Compare USA & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | USA | VCEL |
|---|---|---|
| Founded | N/A | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.7B |
| IPO Year | 1994 | 1996 |
| Metric | USA | VCEL |
|---|---|---|
| Price | $5.63 | $32.29 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $58.50 |
| AVG Volume (30 Days) | ★ 1.1M | 446.2K |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 60.00 |
| EPS | N/A | ★ 0.32 |
| Revenue | N/A | ★ $276,259,000.00 |
| Revenue This Year | N/A | $19.09 |
| Revenue Next Year | N/A | $17.96 |
| P/E Ratio | ★ N/A | $100.34 |
| Revenue Growth | N/A | ★ 16.45 |
| 52 Week Low | $5.64 | $29.24 |
| 52 Week High | $6.96 | $48.75 |
| Indicator | USA | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 24.52 | 34.04 |
| Support Level | N/A | $31.34 |
| Resistance Level | $6.66 | $38.48 |
| Average True Range (ATR) | 0.07 | 1.41 |
| MACD | -0.03 | -0.37 |
| Stochastic Oscillator | 1.27 | 15.85 |
Liberty All Star Equity Fund is a multi-managed fund. Its objective is to provide a high level of current income and long-term capital appreciation through investing principally in a diversified portfolio of equity securities. The fund invests in various sectors, including financials, information technology, healthcare, consumer discretionary, consumer staples, industrials, energy, materials, real estate, utilities, telecommunication, and other services.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.